Last edition
News about "Racura Oncology"
Racura Oncology Advances RC220 to Higher Dose Level in Phase 1 CPACS Cancer Trial
Racura Oncology has received approval from the Safety Review Committee to escalate the dose of investigational cancer therapy RC220 in its phase 1 CPACS clinical trial following positive safety findings in advanced metastatic cancer patients.
Racura Oncology | 19/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members